Avastin plus IFN demonstrated superior median PFS and ORR in mRCC

In the AVOREN study, Avastin plus IFN improved median PFS by 4.8 months (10.2 months vs 5.4 months [HR=0.60; 95% CI, 0.49–0.72; P<0.0001]) and more than doubled ORR vs placebo plus IFN (30% vs 12%, P<0.0001).[1]

mRCC=metastatic renal cell carcinoma; PFS=progression-free survival; ORR=objective response rate; IFN=interferon; HR=hazard ratio; CI=confidence interval.

*Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin.
As of 01/01/2021, national coverage for Avastin is 85%+.